188 related articles for article (PubMed ID: 23056634)
1. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
Luster TA; Mukherjee I; Carrell JA; Cho YH; Gill J; Kelly L; Garcia A; Ward C; Oh L; Ullrich SJ; Migone TS; Humphreys R
PLoS One; 2012; 7(10):e47361. PubMed ID: 23056634
[TBL] [Abstract][Full Text] [Related]
2. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
3. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
[TBL] [Abstract][Full Text] [Related]
5. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
Nimmanapalli R; Lyu MA; Du M; Keating MJ; Rosenblum MG; Gandhi V
Blood; 2007 Mar; 109(6):2557-64. PubMed ID: 17119117
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
7. Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.
Lyu MA; Cheung LH; Hittelman WN; Liu Y; Marks JW; Cho MJ; Rosenblum MG
Cancer Lett; 2012 Sep; 322(2):159-68. PubMed ID: 22388102
[TBL] [Abstract][Full Text] [Related]
8. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
Wen X; Lyu MA; Zhang R; Lu W; Huang Q; Liang D; Rosenblum MG; Li C
Mol Imaging Biol; 2011 Aug; 13(4):721-9. PubMed ID: 20686856
[TBL] [Abstract][Full Text] [Related]
10. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Fu L; Lin-Lee YC; Pham LV; Tamayo A; Yoshimura L; Ford RJ
Blood; 2006 Jun; 107(11):4540-8. PubMed ID: 16497967
[TBL] [Abstract][Full Text] [Related]
11. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.
Yan M; Brady JR; Chan B; Lee WP; Hsu B; Harless S; Cancro M; Grewal IS; Dixit VM
Curr Biol; 2001 Oct; 11(19):1547-52. PubMed ID: 11591325
[TBL] [Abstract][Full Text] [Related]
13. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
Shivakumar L; Ansell S
Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
[TBL] [Abstract][Full Text] [Related]
14. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.
Woodland RT; Fox CJ; Schmidt MR; Hammerman PS; Opferman JT; Korsmeyer SJ; Hilbert DM; Thompson CB
Blood; 2008 Jan; 111(2):750-60. PubMed ID: 17942753
[TBL] [Abstract][Full Text] [Related]
15. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
16. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.
Briones J; Timmerman JM; Hilbert DM; Levy R
Exp Hematol; 2002 Feb; 30(2):135-41. PubMed ID: 11823048
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.
Marsters SA; Yan M; Pitti RM; Haas PE; Dixit VM; Ashkenazi A
Curr Biol; 2000 Jun; 10(13):785-8. PubMed ID: 10898980
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
